Acer Therapeutics IncNASDAQ:ACER
- LAST PRICE2.1000
- TODAY'S CHANGE (%)-0.1200 (-5.4054%)
- Bid / Lots2.0800/ 7
- Ask / Lots2.1000/ 6
- Open / Previous Close2.1900 / 2.2200
- Day Range
- 52 Week Range
- Volume221,895
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACER |
|---|---|---|
| 09:32 ET | 2267 | 2.19 |
| 09:33 ET | 8386 | 2.1898 |
| 09:35 ET | 4027 | 2.16 |
| 09:37 ET | 1400 | 2.15 |
| 09:39 ET | 4250 | 2.15 |
| 09:42 ET | 12607 | 2.12 |
| 09:44 ET | 5982 | 2.14 |
| 09:46 ET | 7510 | 2.11 |
| 09:48 ET | 19618 | 2.09 |
| 09:50 ET | 10532 | 2.097 |
| 09:51 ET | 4000 | 2.09 |
| 09:53 ET | 28046 | 2.04 |
| 09:55 ET | 13792 | 2.05 |
| 09:57 ET | 5703 | 2.08 |
| 10:00 ET | 2090 | 2.1019 |
| 10:02 ET | 10449 | 2.07 |
| 10:04 ET | 1683 | 2.0858 |
| 10:06 ET | 4000 | 2.0912 |
| 10:08 ET | 200 | 2.09 |
| 10:09 ET | 5729 | 2.1202 |
| 10:11 ET | 2881 | 2.14 |
| 10:18 ET | 340 | 2.13 |
| 10:20 ET | 467 | 2.131 |
| 10:24 ET | 1000 | 2.125 |
| 10:27 ET | 1000 | 2.1298 |
| 10:29 ET | 200 | 2.11 |
| 10:31 ET | 100 | 2.12 |
| 10:36 ET | 2000 | 2.11 |
| 10:40 ET | 100 | 2.12 |
| 10:42 ET | 472 | 2.1169 |
| 10:45 ET | 1113 | 2.12 |
| 10:54 ET | 2713 | 2.1 |
| 10:56 ET | 165 | 2.1 |
| 11:02 ET | 300 | 2.105 |
| 11:05 ET | 1232 | 2.11 |
| 11:14 ET | 3854 | 2.09 |
| 11:16 ET | 1200 | 2.08 |
| 11:38 ET | 904 | 2.09 |
| 11:41 ET | 200 | 2.09 |
| 11:43 ET | 217 | 2.1 |
| 11:57 ET | 346 | 2.105 |
| 12:03 ET | 300 | 2.11 |
| 12:06 ET | 1000 | 2.1098 |
| 12:12 ET | 200 | 2.13 |
| 12:14 ET | 3700 | 2.115 |
| 12:15 ET | 2000 | 2.1101 |
| 12:44 ET | 200 | 2.128 |
| 12:51 ET | 100 | 2.1281 |
| 12:57 ET | 1595 | 2.12 |
| 01:04 ET | 500 | 2.12 |
| 01:06 ET | 500 | 2.1299 |
| 01:09 ET | 1900 | 2.13 |
| 01:22 ET | 100 | 2.135 |
| 01:24 ET | 100 | 2.135 |
| 01:29 ET | 1505 | 2.125 |
| 01:31 ET | 200 | 2.11 |
| 01:33 ET | 200 | 2.1151 |
| 01:42 ET | 200 | 2.115 |
| 02:03 ET | 170 | 2.1189 |
| 02:07 ET | 100 | 2.12 |
| 02:09 ET | 100 | 2.13 |
| 02:16 ET | 1100 | 2.13 |
| 02:18 ET | 100 | 2.1299 |
| 02:20 ET | 100 | 2.13 |
| 02:25 ET | 600 | 2.12 |
| 02:32 ET | 203 | 2.1175 |
| 02:38 ET | 150 | 2.1135 |
| 02:39 ET | 14081 | 2.095 |
| 02:41 ET | 1740 | 2.08 |
| 02:45 ET | 500 | 2.09 |
| 02:48 ET | 810 | 2.1 |
| 02:50 ET | 1800 | 2.1 |
Yesterday
Jan 31, 2023
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements, from 8:00AM ET on Tuesday Jan 31, 2023 by PR Newswire
8:00AM ET on Tuesday Jan 31, 2023 by PR Newswire
Jan 17, 2023
Top Premarket Decliners, from 7:46AM ET on Tuesday Jan 17, 2023 by MT Newswires
7:46AM ET on Tuesday Jan 17, 2023 by MT Newswires
Jan 9, 2023
Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones, from 8:30AM ET on Monday Jan 09, 2023 by GlobeNewswire
8:30AM ET on Monday Jan 09, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Acer Therapeutics Inc | 36.3M | -1.5x | --- |
Biora Therapeutics Inc | 36.2M | -0.2x | --- |
Palatin Technologies Inc | 38.7M | -0.9x | --- |
Evogene Ltd | 34.4M | -1.1x | --- |
TRACON Pharmaceuticals Inc | 37.5M | -1.1x | --- |
Avalon Globocare Corp | 31.9M | -2.5x | --- |
Company Information
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate), ACER-801 (osanetant), EDSIVO (celiprolol) and ACER-2820 (emetine). ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for the treatment of induced vasomotor symptoms (iVMS); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19.
Contact Information
- Headquarters
- One Gateway Center (300 Washington St.) Suite 356NEWTON, MA, United States 02458
- Phone
- ---
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Stephen Aselage
- President, Chief Executive Officer, Director
- Chris Schelling
- Chief Financial Officer
- Harry Palmin
- Chief Operating Officer
- Tanya Hayden
- Chief People Officer
- Bernie Paul
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.3M |
|---|---|
Revenue (TTM) | $360.0K |
Shares Outstanding | 16.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.62 |
EPS | $-1.44 |
Book Value | $-0.12 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | 101.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,603.02% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
